Bulletin of Semashko National Research Institute of Public HealthBulletin of Semashko National Research Institute of Public Health2415-84102415-8429FSSBI «N.A. Semashko National Research Institute of Public Health»302910.25742/NRIPH.2023.04.015Научная статьяInsulin pump therapy in clinical practice: the results of a three-year follow-upBarsukovIlia A.palantirr@inbox.ruDeminaAnna A.annagalitskova@gmail.comDrevalAleksandr V.endocrinolog-cab@yandex.ruMoscow Regional Research and Clinical Institute (MONIKI), 61/2 Shchepkina ul., Moscow, Russian Federation151220234909520102025Copyright © 2023,2023Introduction: The attempts to improve the treatment efficacy of diabetes mellitus have led to the development of continuous subcutaneous insulin infusion systems (CSII). Nevertheless, the data on the duration as well as on the discontinuation rate of CSII is limited. Aim: to evaluate the outcomes of insulin pump therapy including the effects on diabetes management and discontinuation rates. Materials and methods: Adults with diabetes mellitus who were switched on insulin pump therapy in Moscow Region in 2015—2019 years. The data about the carbohydrate state and pump therapy discontinuation was received by personal visits, by phone calls or from medical records. The follow-up period was 36 months. Results: Data from 455 patients were received. About 275 (60,4%) patients continued CSII therapy during the first 6 months, but in 36 months only 171 (37,6%) continued the treatment. The main reasons reported were the high cost of monthly consumables (57,6% of patients) and not feeling comfortable wearing the device (29,7%). There was a correlation between monthly consumables supply, diabetic proliferative retinopathy (DPR), and insulin pump discontinuation. Thus, the duration of pump use in patients who were supplied with monthly consumables within state guarantee was 30 ± 1,1 months, in those without supplementation — 16,4 ± 0,9 months (plt;0,01). The mean duration of pump use in patients with DPR was 14 months, in those without DPR — 18 months (р=0,031). The level of glycated hemoglobin decreased on almost 0,6% in insulin pump users during 36 months follow-up (plt;0,01). Conclusion: Despite the increasing accessibility of insulin pumps the current regulatory documents don’t match in several essential aspects, that may lead to the decrease in the effectiveness of therapeutic interventions.diabetes mellitus, insulin pump therapy, glycated hemoglobin, insulin pump discontinuationсахарный диабетпомповая инсулинотерапиягликированный гемоглобинпрекращение использования инсулиновой помпыMcKergow E, Parkin L, Barson DJ, Sharples KJ, Wheeler BJ. Geographic and regional disparities in insulin pump utilization in a setting of universal funding: a New Zealand nationwide study. Acta Diabetol. 2017;54(1):63—71. doi: 10.1007/s00592-016-0912-7Bonfanti R, Lepore G, Bozzetto L, Corsi A, Di Blasi V, Girelli A, et al. Survey on the use of insulin pumps in Italy: comparison between pediatric and adult age groups (IMITA study). Acta Diabetol. 2016;53(3):403—12. doi: 10.1007/s00592-015-0810-4Milburn J, de Lange M, Wiltshire E, Ross P, Rayns J, Tomlinson P, Wu F, Kumarasamy IM, Armishaw J, Wheeler BJ. Evaluating the impact of an insulin pump discontinuation action plan on patient or caregiver confidence and anxiety. J Diabetes Metab Disord. 2019;18(1):81—88. doi: 10.1007/s40200-019-00393-3Almogbel E. Impact of insulin pump therapy on glycemic control among adult Saudi type-1 diabetic patients. An interview-based case-control study. J Family Med Prim Care. 2020;9(2):1013—1019. doi: 10.4103/jfmpc.jfmpc_869_19Evans M, Ceriello A, Danne T, De Block C, DeVries JH, Lind M, Mathieu C, Nørgaard K, Renard E, Wilmot EG. Use of fast-acting insulin aspart in insulin pump therapy in clinical practice. Diabetes Obes Metab. 2019;21(9):2039—2047. doi: 10.1111/dom.13798Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2014;(2):CD009122. doi: 10.1002/14651858.CD009122.pub2REPOSE Study Group. Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE). BMJ. 2017;356:j1285. doi: 10.1136/bmj.j1285Karges B, Schwandt A, Heidtmann B, Kordonouri O, Binder E, Schierloh U, et al. Association of insulin pump therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes. JAMA. 2017;318(14):1358—66 doi: 10.1001/jama.2017.13994Benkhadra K, Alahdab F, Tamhane SU, McCoy RG, Prokop LJ, Murad MH. Continuous subcutaneous insulin infusion versus multiple daily injections in individuals with type 1 diabetes: a systematic review and meta-analysis. Endocrine. 2017;55(1):77—84 doi: 10.1007/s12020-016-1039-xSteineck I, Cederholm J, Eliasson B, et al. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18,168 people with type 1 diabetes: observational study. BMJ. 2015;350:h3234 doi: 10.1136/bmj.h3234Ross PL, Milburn J, Reith DM, Wiltshire E, Wheeler BJ. Clinical review: insulin pump-associated adverse events in adults and children. Acta Diabetol. 2015;52(6):1017—24. doi: 10.1007/s00592-015-0784-2Ross P, Gray AR, Milburn J, Kumarasamy IM, Wu F, Farrand S, et al. Insulin pump-associated adverse events are common, but not associated with glycemic control, socio-economic status, or pump/infusion set type. Acta Diabetol. 2016;53(6):991—8 doi: 10.1007/s00592-016-0897-2Wong JC, Boyle C, DiMeglio LA, Mastrandrea LD, Abel KL, Cengiz E, Cemeroglu PA, Aleppo G, Largay JF, Foster NC, Beck RW, Adi S; T1D Exchange Clinic Network. Evaluation of Pump Discontinuation and Associated Factors in the T1D Exchange Clinic Registry. J Diabetes Sci Technol. 2017;11(2):224—232. doi: 10.1177/1932296816663963Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И. И. Дедова, М. В. Шестаковой, А. Ю. Майорова. 11-й выпуск. М.; 2023. doi: https://doi.org/10.14341/DM13042